Retraction: Mesenchymal Stromal Cells for Tissue-Engineered Tissue and Organ Replacements: Tissue engineering and stem cells (Transplant International, (2012), 25, 4, (369-382), 10.1111/j.1432-2277.2011.01426.x);Mesenchymal stromal cells for tissue-engineered tissue and organ replacements

Transplant International

Volumn 25, Issue 4, 2012, Pages 369-382

  Baiguera, Silvia ^a   Jungebluth, Philipp ^b   Mazzanti, Benedetta ^a   MacChiarini, Paolo ^a,b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

immunogenicity; immunomodulation; mesenchymal stromal cells; tissue engineering

Indexed keywords

CYTOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN;

ADAPTIVE IMMUNITY; CELL CYCLE; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGENETICS; IMMUNOMODULATION; INNATE IMMUNITY; MESENCHYMAL STROMA CELL; NATURAL KILLER CELL; NONHUMAN; ORGAN TRANSPLANTATION; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL; T LYMPHOCYTE; TISSUE ENGINEERING;

EID: 84858441307     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.3389/ti.2024.12843     Document Type: Erratum

References (144)

1. Atala A, Bauer SB, Soker S, Yoo JJ, Retik AB,. Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet 2006; 367: 1241.
2. Pham C, Greenwood J, Cleland H, Woodruff P, Maddern G,. Bioengineered skin substitutes for the management of burns: a systematic review. Burns 2007; 33: 946.
3. Macchiarini P, Jungebluth P, Go T, et al. Clinical transplantation of a tissue-engineered airway. Lancet 2008; 372 (9655): 2023.
4. Langer R, Vacanti JP,. Tissue engineering. Science 1993; 260: 920.
5. Walles T, Giere B, Hofmann M, et al. Experimental generation of a tissue-engineered functional and vascularized trachea. J Thorac Cardiovasc Surg 2004; 128 (6): 900.
6. Komura M, Komura H, Tanaka Y, et al. Human tracheal chondrocytes as a cell source for augmenting stenotic tracheal segments: the first feasibility study in an in vivo culture system. Pediatr Surg Int 2008; 24 (10): 1117.
7. Mertsching H, Schanz J, Steger V, et al. Generation and transplantation of an autologous vascularized bioartificial human tissue. Transplantation 2009; 88 (2): 203.
8. Ratajczak MZ, Zuba-Surma EK, Wysoczynski M, et al. Hunt for pluripotent stem cell -regenerative medicine search for almighty cell. J Autoimmun 2008; 30 (3): 151.
9. Ehnert S, Glanemann M, Schmitt A, et al. The possible use of stem cells in regenerative medicine: dream or reality? Langenbecks Arch Surg 2009; 394 (6): 985.
10. Díaz-Prado S, Muiños-López E, Hermida-Gómez T, et al. Human amniotic membrane as an alternative source of stem cells for regenerative medicine. Differentiation 2011; 81 (3): 162.
11. De C, Bartsch G Jr, Siddiqui MM, et al. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 2007; 25 (1): 100.
12. Cananzi M, Atala A, De Coppi P,. Stem cells derived from amniotic fluid: new potentials in regenerative medicine. Reprod Biomed Online 2009; 18: 17.
13. Zhao T, Zhang ZN, Rong Z, Xu Y,. Immunogenicity of induced pluripotent stem cells. Nature 2011; 474 (7350): 212.
14. da S, Chagastelles PC, Nardi NB,. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006; 11: 2204.
15. Dominici M, Le B, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8 (4): 315.
16. Anjos-Afonso F, Bonnet D,. Nonhematopoietic/endothelial SSEA-1+ cells define the most primitive progenitors in the adult murine bone marrow mesenchymal compartment. Blood 2007; 109 (3): 1298.
17. Reyes M, Lund T, Lenvik T, Aguiar D, Koodie L, Verfaillie CM,. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001; 98: 2615.
18. Kadivar M, Khatami S, Mortazavi Y, Shokrgozar MA, Taghikhani M, Soleimani M,. In vitro cardiomyogenic potential of human umbilical vein-derived mesenchymal stem cells. Biochem Biophys Res Commun 2006; 340: 639.
19. Kang XQ, Zang WJ, Bao LJ, et al. Fibroblast growth factor-4 and hepatocyte growth factor induce differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocytes. World J Gastroenterol 2005; 11: 7461.
20. Hung SC, Chen H, Pan CY, Tsai MJ, Kao LS, Ma HL,. In vitro differentiation of size-sieved stem cells into electrically active neural cells. Stem Cells 2002; 20: 522.
21. Bang OY, Lee JS, Lee PH, Lee G,. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005; 57: 874.
22. Horwitz EW, Gordon PL, Koo WKK, et al. Isolated allogeneic bone marrow-derived mesenchymal stem cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 2002; 99: 8932.
23. Herrera MB, Bussolati B, Bruno S, Fonsato V, Romanazzi GM, Camussi G,. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med 2004; 14: 1035.
24. Sacchetti B, Funari A, Michienzi S, et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007; 131: 324.
25. Crisan M, Yap S, Casteilla L, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008; 3: 301.
26. Caplan AI,. Why are MSCs therapeutic? New data: new insight J Pathol 2009; 217: 318.
27. Nakanishi C, Yamagishi M, Yamahara K, et al. Activation of cardiac progenitor cells through paracrine effects of mesenchymal stem cells. Biochem Biophys Res Commun 2008; 374: 11.
28. Uccelli A, Moretta L, Pistoia V,. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 2006; 36 (10): 2566.
29. Tyndall A, Walker UA, Cope A, et al. Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Res Ther. 2007; 9 (1): 301.
30. Le B, Tammik C, Rosendahl K, Zetterberg E, Ringdén O,. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31 (10): 890.
31. Rasmusson I,. Immune modulation by mesenchymal stem cells. Exp Cell Res 2006; 312 (12): 2169.
32. Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005; 105: 2214.
33. Aggarwal S, Pittenger MF,. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815.
34. Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F,. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 2007; 83: 71.
35. Jiang XX, Zhang Y, Liu B, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120.
36. Le B, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439.
37. Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W,. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002; 30: 215.
38. Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722.
39. Groh ME, Maitra B, Szekely E, Koc ON,. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 2005; 33: 928.
40. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP,. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol 2009; 156 (1): 149.
41. Djouad F, Charbonnier LM, Bouffi C, et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007; 25: 2025.
42. English K, Barry FP, Mahon BP,. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett 2008; 115 (1): 50.
43. Zhang B, Liu R, Shi D, et al. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood 2009; 113 (1): 46.
44. Li H, Guo Z, Jiang X, Zhu H, Li X, Mao N,. Mesenchymal stem cells alter migratory property of T and dendritic cells to delay the development of murine lethal acute graft-versus-host disease. Stem Cells 2008; 26: 2531.
45. Popp FC, Eggenhofer E, Renner P, et al. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol 2008; 20: 55.
46. Rossignol J, Boyer C, Thinard R, et al. Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation. J Cell Mol Med 2009; 13: 2547.
47. Li FR, Wang XG, Deng CY, Qi H, Ren LL, Zhou HX,. Immune modulation of co-transplantation mesenchymal stem cells with islet on T and dendritic cells. Clin Exp Immunol 2010; 161: 357.
48. Chen L, Tredget EE, Wu PY, Wu Y,. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE 2008; 3: e1886.
49. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE,. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 2006; 177 (4): 2080.
50. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A,. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 2007; 92: 881.
51. Zhang W, Ge W, Li C, et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 2004; 13 (3): 263.
52. Angoulvant D, Clerc A, Benchalal S, et al. Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens. Biorheology 2004; 41: 469.
53. Crop M, Baan C, IJzermans J, Alwayn I, Weimar W, Hoogduijn M,. Donor-derived mesenchymal stem cells suppress anti-donor reactivity in transplantation recipients. Transpl Int 2007; 20: 67.
54. Aldinucci A, Rizzetto L, Pieri L, et al. Inhibition of immune synapse by altered dendritic cell actin distribution: a new pathway of mesenchymal stem cell immune regulation. J Immunol 2010; 185: 5102.
55. Kim JJ, Bagarazzi ML, Trivedi N, et al. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat Biotechnol 1997; 15: 641.
56. 2. Blood 2008; 111: 1327.
57. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L,. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006; 107 (4): 1484.
58. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M,. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74.
59. 2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15: 42.
60. Pevsner-Fischer M, Morad V, Cohen-Sfady M, et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 2007; 109 (4): 1422.
61. Liotta F, Angeli R, Cosmi L, et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 2008; 26 (1): 279.
62. Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka ES, Scandurro AB,. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 2008; 26 (1): 99.
63. Gieseke F, Böhringer J, Bussolari R, Dominici M, Handgretinger R, Müller I,. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 2010; 116: 3770.
64. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC,. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003; 75: 389.
65. Klyushnenkova E, Mosca JD, Zernetkina V, et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 2005; 12: 47.
66. Batten P, Sarathchandra P, Antoniw JW, et al. Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. Tissue Eng 2006; 12 (8): 2263.
67. Rasmusson I, Ringden O, Sundberg B, Le Blanc K,. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76: 1208.
68. Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P,. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 2003; 171: 3426.
69. Chamberlain G, Fox J, Ashton B, Middelton J,. Concise review. Mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007; 25: 2739.
70. Ghannam S, Pène J, Torcy-Moquet G, Jorgensen C, Yssel H,. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 2010; 185: 302.
71. Di N, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838.
72. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D,. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103: 4619.
73. Hainz U, Jurgens B, Heitger A,. The role of indoleamine 2,3-dioxygenase in transplantation. Transpl Int 2007; 20: 118.
74. Ryan JM, Barry FP, Murphy JM, Mahon BP,. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm 2005; 2: 8.
75. Suva D, Passweg J, Arnaudeau S, Hoffmeyer P, Kindler V,. In vitro activated human T lymphocytes very efficiently attach to allogenic multipotent mesenchymal stromal cells and transmigrate under them. J Cell Physiol 2008; 214 (3): 588.
76. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F,. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105 (7): 2821.
77. Benvenuto F, Ferrari S, Gerdoni E, et al. Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells 2007; 25: 1753.
78. Di I, Del Papa B, De Ioanni M, et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 2008; 36: 309.
79. Maccario R, Podesta M, Moretta A, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005; 90: 516.
80. Casiraghi F, Azzollini N, Cassis P, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008; 181: 3933.
81. Ge W, Jiang J, Baroja ML, et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant 2009; 9 (8): 1760.
82. Boumaza I, Srinivasan S, Witt WT, et al. Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia. J Autoimmun 2009; 32: 33.
83. Madec AM, Mallone R, Afonso G, et al. Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 2009; 52: 1391.
84. Ringdén O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81 (10): 1390.
85. van L, Tyndall A,. Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford) 2006; 45: 1187.
86. Uccelli A, Moretta L, Pistoia V,. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8: 726.
87. Togel F, Cohen A, Zhang P, Yang Y, Hu Z, Westenfelder C,. Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury. Stem Cells Dev 2009; 18: 475.
88. Tyndall A, Gratwohl A,. Adult stem cell transplantation in autoimmune disease. Curr Opin Hematol 2009; 16: 285.
89. Zhou H, Guo M, Bian C, et al. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol Blood Marrow Transplant 2010; 16: 403.
90. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367.
91. Tabera S, Perez-Simon JA, Diez-Campelo M, et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica 2008; 93 (9): 1301.
92. Le B, Ringden O,. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 321.
93. Traggiai E, Volpi S, Schena F, et al. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 2008; 26: 562.
94. Krampera M, Cosmi L, Angeli R, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24 (2): 386.
95. Yoo KH, Jang IK, Lee MW, et al. Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol 2009; 259: 150.
96. Jones S, Horwood N, Cope A, Dazzi F,. The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J Immunol 2007; 179: 2824.
97. Wolbank S, van G, Grillari-Voglauer R, Peterbauer-Scherb A,. Alternative sources of adult stem cells: human amniotic membrane. Adv Biochem Eng Biotechnol 2010; 123: 1.
98. Ankrum J, Karp JM,. Mesenchymal stem cell therapy: two steps forward, one step back. Trends Mol Med 2010; 16: 203.
99. Lazarus HM, Koc ON, Devine SM, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11 (5): 389.
100. Ohtaki H, Ylostalo JH, Foraker JE, et al. Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses. Proc Natl Acad Sci USA 2008; 105: 14638.
101. Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005; 106: 1755.
102. Rafei M, Campeau PM, Aguilar-Mahecha A, et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol 2009; 182: 5994.
103. Chen L, Tredget EE, Liu C, Wu Y,. Analysis of allogenicity of mesenchymal stem cells in engraftment and wound healing in mice. PLoS ONE 2009; 4: e7119.
104. Coyne TM, Marcus AJ, Woodbury D, et al. Marrow stromal cells transplanted to the adult brain are rejected by an inflammatory response and transfer donor labels to host neurons and glia. Stem Cells 2006; 24: 2483.
105. Liu H, Kemeny DM, Heng BC, Ouyang HW, Melendez AJ, Cao T,. The immunogenicity and immunomodulatory function of osteogenic cells differentiated from mesenchymal stem cells. J Immunol 2006; 176: 2864.
106. Le B, Frassoni F, Ball L, et al. Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371 (9624): 1579.
107. Berman DM, Willman MA, Han DM, Kleiner G, Kenyon NM, Cabrera O,. Mesenchymal stem cells enhance allogeneic islet engraftment in nonhuman primates. Diabetes 2010; 59: 2558.
108. Poncelet AJ, Nizet Y, Vercruysse J, Hiel AL, Saliez A, Gianello P,. Inhibition of humoral response to allogeneic porcine mesenchymal stem cell with 12 days of tacrolimus. Transplantation 2008; 86 (11): 1586.
109. Sbano P, Cuccia A, Mazzanti B, et al. Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Arch Dermatol Res 2008; 300 (3): 115.
110. Eggenhofer E, Steinmann JF, Renner P, et al. Mesenchymal stem cells together with mycophenolatem of etilinhibit antigen presenting cell and T cell infiltration into allogeneic heart grafts. Transpl Immunol 2011; 24 (3): 157.
111. Ponte AL, Marais E, Gallay N, et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 2007; 25 (7): 1737.
112. Cho PS, Messina DJ, Hirsh EL, et al. Immunogenicity of umbilical cord tissue derived cells. Blood 2008; 111: 430.
113. Rafei M, Birman E, Forner K, Galipeau J,. Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol Ther 2009; 17: 1799.
114. English K, Barry FP, Field-Corbett CP, et al. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 2007; 110 (2): 91.
115. Ryan JM, Barry F, Murphy JM, Mahon BP,. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007; 149: 353.
116. Polchert D, Sobinsky J, Douglas G, et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 2008; 38: 1745.
117. Opitz CA, Litzenburger UM, Lutz C, et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 2009; 27: 909.
118. Chan JL, Tang KC, Patel AP, et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-{gamma}. Blood 2006; 107 (12): 4817.
119. Stagg J, Pommey S, Eliopoulos N, et al. Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood 2006; 107 (6): 2570.
120. Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2 (2): 141.
121. Kemp K, Gray E, Mallam E, et al. Inflammatory cytokine induced regulation of superoxide dismutase 3 expression by human mesenchymal stem cells. Stem Cell Rev 2010; 6 (4): 548.
122. Fodor WL,. Tissue engineering and cell based therapies, from the bench to the clinic: the potential to replace, repair and regenerate. Reprod Biol Endocrinol 2003; 1: 102.
123. Corona BT, Ward CL, Harrison BS, Christ GJ,. Regenerative medicine: basic concepts, current status, and future applications. J Invest Med 2010; 58 (7): 849.
124. Perán M, Marchal JA, Rodríguez-Serrano F, Alvarez P, Aránega A,. Transdifferentiation: why and how? Cell Biol Int 2011; 35 (4): 373.
125. Fang TC, Alison MR, Wright NA, Poulsom R,. Adult stem cell plasticity: will engineered tissues be rejected? Int J Exp Pathol 2004; 85 (3): 115.
126. Pessina A, Gribaldo L,. The key role of adult stem cells: therapeutic perspectives. Curr Med Res Opin 2006; 22 (11): 2287.
127. Ilic D, Polak JM,. Stem cells in regenerative medicine: introduction. Br Med Bull 2011; 98: 117.
128. Banas RA, Trumpower C, Bentlejewski C, Marshall V, Sing G, Zeevi A,. Immunogenicity and immunomodulatory effects of amnion-derived multipotent progenitor cells. Hum Immunol 2008; 69 (6): 321.
129. Leeb C, Jurga M, McGuckin C, Moriggl R, Kenner L,. Promising new sources for pluripotent stem cells. Stem Cell Rev 2010; 6 (1): 15.
130. Broxmeyer HE,. Umbilical cord transplantation: epilogue. Semin Hematol 2010; 47 (1): 97.
131. Ruhil S, Kumar V, Rathee P,. Umbilical cord stem cell: an overview. Curr Pharm Biotechnol 2009; 10 (3): 327.
132. Pera MF, Reubinoff B, Trounson A,. Human embryonic stem cells. J Cell Sci 2000; 1: 5.
133. O'Donoghue K, Fisk NM,. Fetal stem cells. Best Pract Res Clin Obstet Gynaecol 2004; 18 (6): 853.
134. Kim K, Doi A, Wen B, et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010; 467 (7313): 285.
135. Hussein SM, Nagy K, Nagy A,. Human induced pluripotent stem cells: the past, present, and future. Clin Pharmacol Ther 2011; 89 (5): 741.
136. Wu SM, Hochedlinger K,. Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat Cell Biol 2011; 13 (5): 497.
137. Le Blanc K, Ringden O,. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007; 262: 509.
138. Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102: 3837.
139. Isakova IA, Dufour J, Lanclos C, Bruhn J, Phinney DG,. Cell-dose-dependent increases in circulating levels of immune effector cells in rhesus macaques following intracranial injection of allogeneic MSCs. Exp Hematol 2010; 38: 957.
140. Camp DM, Loeffler DA, Farrah DM, Borneman JN, LeWitt PA,. Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson's disease. J Neuroinflammation 2009; 6: 17.
141. Imanishi Y, Saito A, Komoda H, et al. Allogenic mesenchymal stem cell transplantation has a therapeutic effect in acute myocardial infarction in rats. J Mol Cell Cardiol 2008; 44: 662.
142. Badillo AT, Beggs KJ, Javazon EH, Tebbets JC, Flake AW,. Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response. Biol Blood Marrow Transplant 2007; 13: 412.
143. Beggs KJ, Lyubimov A, Borneman JN, et al. Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons. Cell Transplant 2006; 15: 711.
144. Zangi L, Margalit R, Reich-Zeliger S, et al. Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cells 2009; 27: 2865.